Bal Pharma Limited

BALPHARMA

INE083D01012

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:53 28/06/2024 pm IST			5-day change	1st Jan Change
117.5 ^INR	+0.69%		-1.96%	+16.92%

28/06	Bal Pharma Limited Announces the Cessation of C. V. Srinivas as Independent Director, Chairman/Member of the Audit Committee, Nomination and Remuneration Committee, Stake Holders Relationship Committee & Corporate Social Responsibility Committees	CI
28/05	Bal Pharma Limited Recommends Dividend	CI

Bal Pharma Limited Recommends Dividend

May 28, 2024 at 06:16 pm IST

Bal Pharma Limited recommended dividend of INR 1.20/- per equity share of INR 10/- each i.e 12%, which is subject to the approval of members at the ensuing Annual General Meeting of the Company.

Latest news about Bal Pharma Limited

Bal Pharma Limited Announces the Cessation of C. V. Srinivas as Independent Director, Chairman/Member of the Audit Committee, Nomination and Remuneration Committee, Stake Holders Relationship Committee & Corporate Social Responsibility Committees	28/06	CI
Bal Pharma Limited Recommends Dividend	28/05	CI
Bal Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	28/05	CI
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08/11	CI
Bal Pharma Limited Approves Dividend	25/23/25	CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Bal Pharma Limited Appoints Abdul Basith as Company Secretary and Compliance Officer	17/23/17	CI
Bal Pharma Limited Appoints Nicola Neeladri as Additional Director	01/23/01	CI
Bal Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	29/23/29	CI
Bal Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/23/29	CI
Bal Pharma Limited Recommends Dividend	29/23/29	CI
Bal Pharma Limited Announces Resignation of Mrs.Preeti Singh as Company Secretary	15/23/15	CI
Acuite Keeps BBB- Rating on Bal Pharma's Bank Loans; Outlook Stable	25/23/25	MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	06/23/06	CI
Bal Pharma CFO Resigns	25/22/25	MT
Bal Pharma Limited Announces Resignation of Mr. G. Rengarajan as Chief Financial Officer	24/22/24	CI
Bal Pharma Limited Reports Earnings Results for the Half Year Ended September 30, 2022	14/22/14	CI
Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Bal Pharma Limited Declares Dividend	19/22/19	CI
Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	11/22/11	CI
Bal Pharma Limited Appoints Kotian Chittananda Damodar as Additional Director (Non Independent)	30/22/30	CI
Bal Pharma Limited Recommends Dividend	30/22/30	CI
Acuite Upgrades Rating on Bal Pharma's Fund-Based Financing to BBB-; Lowers Outlook to Stable	22/22/22	MT
Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	10/22/10	CI

Bal Pharma Limited is a pharmaceutical company, which is engaged in manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It is specialized in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers range of APIs includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers range of formulations products covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAL PHARMA LIMITED	+16.92%	2.19Cr
ELI LILLY AND COMPANY	+55.32%	82TCr
JOHNSON & JOHNSON	-6.75%	35TCr
MERCK & CO., INC.	+13.56%	33TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
ROCHE HOLDING AG	+2.04%	23TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr
PFIZER, INC.	-2.81%	16TCr